A closer look at Quintessential Capital Management and their accusations against Cassava Sciences

#Cassava, #simufilam, #SAVA, #Alzheimer, #Alzheimertreatment, #QCM, #HealthWealth

In this episode we are taking a closer look at some of the allegations made by Qunintessential Capital Management regarding Cassava and its clinical trials. We take a closer look at QCM, their main business model and how they go about what they do.
Then we explore how patient recruitment generally takes place and the role of "professional" patients. We wrap up with putting the patient honoraria which QCM claimed are excessive into perspective.

Chapters:
0:00 Introduction
0:55 Who are Quintessential Capital Management? Do they do what they write?
4:04 QCM on LinkedIn
06:45 QCM on YouTube
10:41 QCM Report on Cassava and cheap argumentation
14:48 Drug Development Process and the Role of Clinical Trial Participants
20:09 Cassava Trials called for Mild to Moderate Alzheimer Patients
21:42 QCM reporting on patient recruitment process in Cassava studies when no recruiting took place
24:31 Review of "excessive" clinical trial participant honoraria

References:
https://www.qcmfunds.com/cassava-sciences-sava-game-over/